Paul Tudor Jones's DXCM Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 69.15 M shares of DexCom, Inc. (DXCM) worth $63.06 M, representing 0.11% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in DXCM, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 69.15 M shares. Largest reduction occurred in Q1 2018, reducing 93,144 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's DexCom (DXCM) Holding Value Over Time
Track share changes against reported price movement
Quarterly DexCom (DXCM) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2013 | +32,236 | New Buy | 32,236 | $8.84 |
| Q1 2014 | -3,444 | Reduce 10.68% | 28,792 | $10.35 |
| Q2 2014 | -28,792 | Sold Out | 0 | $0.00 |
| Q3 2015 | +39,404 | New Buy | 39,404 | $21.47 |
| Q4 2015 | -39,404 | Sold Out | 0 | $0.00 |
| Q4 2017 | +111,416 | New Buy | 111,416 | $14.35 |
| Q1 2018 | -93,144 | Reduce 83.60% | 18,272 | $18.55 |
| Q2 2018 | +146,304 | Add 800.70% | 164,576 | $23.75 |
| Q3 2018 | -89,540 | Reduce 54.41% | 75,036 | $35.76 |
| Q4 2018 | +76,624 | Add 102.12% | 151,660 | $29.95 |
| Q1 2019 | -83,640 | Reduce 55.15% | 68,020 | $29.77 |
| Q2 2019 | -57,368 | Reduce 84.34% | 10,652 | $37.46 |
| Q3 2019 | -10,652 | Sold Out | 0 | $0.00 |
| Q4 2019 | +33,888 | New Buy | 33,888 | $54.68 |
| Q1 2020 | +2,700 | Add 7.97% | 36,588 | $67.32 |
| Q2 2020 | -26,980 | Reduce 73.74% | 9,608 | $101.37 |
| Q3 2020 | -9,608 | Sold Out | 0 | $0.00 |
| Q3 2021 | +15,776 | New Buy | 15,776 | $136.73 |
| Q4 2021 | +15,304 | Add 97.01% | 31,080 | $134.23 |
| Q1 2022 | -31,080 | Sold Out | 0 | $0.00 |
| Q2 2022 | +23,112 | New Buy | 23,112 | $74.55 |
| Q3 2022 | -2,779 | Reduce 12.02% | 20,333 | $80.56 |
| Q4 2022 | -13,933 | Reduce 68.52% | 6,400 | $0.11 |
| Q1 2023 | -1,778 | Reduce 27.78% | 4,622 | $0.12 |
| Q2 2023 | +8,235 | Add 178.17% | 12,857 | $128.51 |
| Q3 2023 | -12,857 | Sold Out | 0 | $0.00 |
| Q4 2023 | +38,770 | New Buy | 38,770 | $124.09 |
| Q1 2024 | -38,770 | Sold Out | 0 | $0.00 |
| Q3 2025 | +69.15 M | New Buy | 69.15 M | $0.91 |
Paul Tudor Jones's DexCom Investment FAQs
Paul Tudor Jones first purchased DexCom, Inc. (DXCM) in Q4 2013, acquiring 32,236 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held DexCom, Inc. (DXCM) for 29 quarters since Q4 2013.
Paul Tudor Jones's largest addition to DexCom, Inc. (DXCM) was in Q3 2025, adding 69,150,000 shares worth $63.06 M.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 69,150,000 shares of DexCom, Inc. (DXCM), valued at approximately $63.06 M.
As of the Q3 2025 filing, DexCom, Inc. (DXCM) represents approximately 0.11% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in DexCom, Inc. (DXCM) was 69,150,000 shares, as reported at the end of Q3 2025.